keyword
MENU ▼
Read by QxMD icon Read
search

Ebola vaccine

keyword
https://www.readbyqxmd.com/read/29346369/the-rise-of-neglected-tropical-diseases-in-the-new-texas
#1
REVIEW
Peter J Hotez
Within the last five years, the State of Texas has experienced either transmission or outbreaks of Ebola, chikungunya, West Nile, and Zika virus infections. Autochthonous transmission of neglected parasitic and bacterial diseases has also become increasingly reported. The rise of such emerging and neglected tropical diseases (NTDs) has not occurred by accident but instead reflects rapidly evolving changes and shifts in a "new" Texas beset by modern and globalizing forces that include rapid expansions in population together with urbanization and human migrations, altered transportation patterns, climate change, steeply declining vaccination rates, and a new paradigm of poverty known as "blue marble health...
January 2018: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29341945/lessons-about-causes-and-management-of-an-ebola-outbreak
#2
Aida Elargoubi, Anis W Belhaj Khelifa, Ons Haddad, Salma Mhalla, Nabil Sakly, Maha Mastouri
Ebola virus disease (EVD) is one of the deadliest viral diseases. It is characterized by a high mortality rate due to the lack of effective and safe treatments or vaccines and its ability to spread at an unstoppable pace. The West Africa outbreak ended but the disease may strike again at any time. The latest epidemic was, by far, the deadliest to date. The most concern was why this outbreak was so different from the previous ones. We proposed in this review firstly to summarize the principal causes of its unprecedented spread and secondly to identify the steps for an effective management approach of a future Ebola outbreak...
December 20, 2017: Folia Medica
https://www.readbyqxmd.com/read/29339750/a-single-dose-of-modified-vaccinia-ankara-expressing-ebola-virus-like-particles-protects-nonhuman-primates-from-lethal-ebola-virus-challenge
#3
Arban Domi, Friederike Feldmann, Rahul Basu, Nathanael McCurley, Kyle Shifflett, Jackson Emanuel, Michael S Hellerstein, Farshad Guirakhoo, Chiara Orlandi, Robin Flinko, George K Lewis, Patrick W Hanley, Heinz Feldmann, Harriet L Robinson, Andrea Marzi
Ebola virus (EBOV), isolate Makona, was the causative agent of the West African epidemic devastating predominantly Guinea, Liberia and Sierra Leone from 2013-2016. While several experimental vaccine and treatment approaches have been accelerated through human clinical trials, there is still no approved countermeasure available against this disease. Here, we report the construction and preclinical efficacy testing of a novel recombinant modified vaccinia Ankara (MVA)-based vaccine expressing the EBOV-Makona glycoprotein GP and matrix protein VP40 (MVA-EBOV)...
January 16, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29333950/willingness-to-pay-for-an-ebola-vaccine-during-the-2014-2016-ebola-outbreak-in-west-africa-results-from-a-u-s-national-sample
#4
Julia E Painter, Michael E von Fricken, Suyane Viana de O Mesquita, Ralph J DiClemente
The 2014-2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S. national sample during the recent Ebola outbreak. From April 30-May 8, 2015, a national survey was conducted using the GfK Group's KnowlegePanel®. Main outcome measures included willingness to pay at least $1; more than $50; and more than $100 for an Ebola vaccine. Analyses were conducted using weighted multivariable logistic regression...
January 15, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29303554/a-serological-point-of-care-test-for-the-detection-of-igg-antibodies-against-ebola-virus-in-human-survivors
#5
Polina Brangel, Ariel Sobarzo, Claudio Parolo, Benjamin S Miller, Philip D Howes, Sigal Gelkop, Julius J Lutwama, John M Dye, Rachel A McKendry, Leslie Lobel, Molly M Stevens
Ebola virus disease causes widespread and highly fatal epidemics in human populations. Today, there is still great need for point-of-care tests for diagnosis, patient management and surveillance, both during and post outbreaks. We present a point-of-care test comprising an immunochromatographic strip and a smartphone reader, which detects and semiquantifies Ebola-specific antibodies in human survivors. We developed a Sudan virus glycoprotein monoplex platform and validated it using sera from 90 human survivors and 31 local noninfected controls...
January 5, 2018: ACS Nano
https://www.readbyqxmd.com/read/29297408/nubia-s-mother-being-pregnant-in-the-time-of-experimental-vaccines-and-therapeutics-for-ebola
#6
Séverine Caluwaerts
During the 2014-2016 Ebola epidemic, Médecins Sans Frontières (MSF) treated Ebola-positive pregnant women in its Ebola Treatment Centers (ETCs). For pregnant women with confirmed Ebola virus disease, inclusion in clinical vaccine/drug/therapeutic trials was complicated. Despite their extremely high Ebola-related mortality in previous epidemics (89-93%) and a neonatal mortality of 100%, theoretical concerns about safety of vaccines and therapeutics in pregnancy were invoked, limiting pregnant women's access to an experimental live attenuated vaccine and brincidofovir, an experimental antiviral...
December 14, 2017: Reproductive Health
https://www.readbyqxmd.com/read/29297366/protected-to-death-systematic-exclusion-of-pregnant-women-from-ebola-virus-disease-trials
#7
Melba F Gomes, Vânia de la Fuente-Núñez, Abha Saxena, Annette C Kuesel
BACKGROUND: For 30 years, women have sought equal opportunity to be included in trials so that drugs are equitably studied in women as well as men; regulatory guidelines have changed accordingly. Pregnant women, however, continue to be excluded from trials for non-obstetric conditions, though they have been included for trials of life-threatening diseases because prospects for maternal survival outweighed potential fetal risks. Ebola virus disease is a life-threatening infection without approved treatments or vaccines...
December 14, 2017: Reproductive Health
https://www.readbyqxmd.com/read/29291209/recent-advances-in-vaccine-development-against-ebola-threat-as-bioweapon
#8
EDITORIAL
Prachi Gera, Ankit Gupta, Priyanka Verma, Joginder Singh, Jeena Gupta
With the increasing rate of Ebola virus appearance, with multiple natural outbreaks of Ebola hemorrhagic fever, it is worthy of consideration as bioweapon by anti-national groups. Further, with the non-availability of the vaccines against Ebola virus, concerns about the public health emerge. In this regard, this review summarizes the structure, genetics and potential of Ebola virus to be used as a bioweapon. We highlight the recent advances in the treatment strategies and vaccine development against Ebola virus...
September 2017: Virusdisease
https://www.readbyqxmd.com/read/29281112/modified-mrna-based-vaccines-elicit-robust-immune-responses-and-protect-guinea-pigs-from-ebola-virus-disease
#9
Michelle Meyer, Eric Huang, Olga Yuzhakov, Palaniappan Ramanathan, Giuseppe Ciaramella, Alexander Bukreyev
Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection...
December 21, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29274250/an-exosome-based-vaccine-platform-imparts-cytotoxic-t-lymphocyte-immunity-against-viral-antigens
#10
Simona Anticoli, Francesco Manfredi, Chiara Chiozzini, Claudia Arenaccio, Eleonora Olivetta, Flavia Ferrantelli, Antonio Capocefalo, Emiliana Falcone, Anna Ruggieri, Maurizio Federico
Exosomes are 50-150 nm sized nanovesicles released by all eukaryotic cells. We very recently described a method to engineer exosomes in vivo with the E7 protein of Human Papilloma Virus (HPV). This technique consists in the intramuscular injection of a DNA vector expressing HPV-E7 fused at the C-terminus of an exosome-anchoring protein, i.e., Nefmut , we previously characterized for its high levels of incorporation in exosomes. In this configuration, the ∼11 kDa E7 protein elicited a both strong and effective antigen-specific cytotoxic T lymphocyte (CTL) immunity...
December 23, 2017: Biotechnology Journal
https://www.readbyqxmd.com/read/29260690/emergence-of-vaccine-derived-polioviruses-during-ebola-virus-disease-outbreak-guinea-2014-2015
#11
Maria Dolores Fernandez-Garcia, Manasi Majumdar, Ousmane Kebe, Aichatou D Fall, Moussa Kone, Mouctar Kande, Moustapha Dabo, Mohamed Salif Sylla, Djenou Sompare, Wayne Howard, Ousmane Faye, Javier Martin, Kader Ndiaye
During the 2014-2015 outbreak of Ebola virus disease in Guinea, 13 type 2 circulating vaccine-derived polioviruses (cVDPVs) were isolated from 6 polio patients and 7 healthy contacts. To clarify the genetic properties of cVDPVs and their emergence, we combined epidemiologic and virologic data for polio cases in Guinea. Deviation of public health resources to the Ebola outbreak disrupted polio vaccination programs and surveillance activities, which fueled the spread of neurovirulent VDPVs in an area of low vaccination coverage and immunity...
January 2018: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/29208326/a-review-on-the-antagonist-ebola-a-prophylactic-approach
#12
REVIEW
Fatima Nazish Khan, Sahar Qazi, Khushnuma Tanveer, Khalid Raza
Ebola virus (EBOV), a member of Filoviridae virus family under the genus Ebolavirus, has emerged as a dangerous and potential threat to human health globally. It causes a severe and deadly hemorrhagic fever in humans and other mammals, called Ebola Virus Disease (EVD). In recent outbreaks of EVD, there has been loss of large numbers of individual's life. Therefore, EBOV has attracted researchers and increased interests in developing new models for virus evolution, and therapies. The EBOV interacts with the immune system of the host which led to understand how the virus functions and effects immune system behaviour...
December 2, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29206076/assessment-of-the-ability-of-v920-recombinant-vesicular-stomatitis-zaire-ebolavirus-vaccine-to-replicate-in-relevant-arthropod-cell-cultures-and-vector-species
#13
Nicholas A Bergren, Megan R Miller, Thomas P Monath, Rebekah C Kading
V920, rVSVΔG-ZEBOV-GP, is a recombinant vesicular stomatitis-Zaire ebolavirus vaccine which has shown an acceptable safety profile and provides a protective immune response against Ebola virus disease (EVD) induced by Zaire ebolavirus in humans. The purpose of this study was to determine whether the V920 vaccine is capable of replicating in arthropod cell cultures of relevant vector species and of replicating in live mosquitoes. While the V920 vaccine replicated well in Vero cells, no replication was observed in Anopheles or Aedes mosquito, Culicoides biting midge, or Lutzomyia sand fly cells, nor in live Culex or Aedes mosquitoes following exposure through intrathoracic inoculation or feeding on a high-titer infectious blood meal...
December 5, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29199040/progress-towards-a-vaccine-against-ebola-to-meet-emergency-medical-countermeasure-needs
#14
Daniel N Wolfe, Amanda G Zarrabian, Gary L Disbrow, Eric M Espeland
The Ebola virus epidemic in West Africa proved to be the largest in the history of filovirus outbreaks, causing the World Health Organization to declare a public health emergency of international concern in August of 2014. In collaboration with domestic and international partners, the Biomedical Advanced Research and Development Authority (BARDA) initiated several vaccine development projects in support of the overall response efforts. The urgency associated with the epidemic triggered the clinical evaluation of lead vaccine candidates starting in late 2014...
November 30, 2017: Vaccine
https://www.readbyqxmd.com/read/29177461/rigorous-clinical-trial-design-in-public-health-emergencies-is-essential
#15
Susan S Ellenberg, Gerald T Keusch, Abdel G Babiker, Kathryn M Edwards, Roger J Lewis, Jens D Lundgren, Charles D Wells, Fred Wabwire-Mangen, Keith P W J McAdam
Randomized clinical trials are the most reliable approaches to evaluating the effects of new treatments and vaccines. During the 2014-15 West African Ebola epidemic, many argued that such trials were neither ethical nor feasible in an environment of limited health infrastructure and severe disease with a high fatality rate. Consensus among the numerous organizations providing help to the affected areas was never achieved, resulting in fragmented collaboration, delayed study initiation, and ultimately failure to provide definitive evidence on the efficacy of treatments and vaccines...
November 21, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29175127/retro-2-and-its-dihydroquinazolinone-derivatives-inhibit-filovirus-infection
#16
Olena Shtanko, Yasuteru Sakurai, Ann N Reyes, Romain Noël, Jean-Christophe Cintrat, Daniel Gillet, Julien Barbier, Robert A Davey
Members of the family Filoviridae cause severe, often fatal disease in humans, for which there are no approved vaccines and only a few experimental drugs tested in animal models. Retro-2, a small molecule that inhibits retrograde trafficking of bacterial and plant toxins inside host cells, has been demonstrated to be effective against a range of bacterial and virus pathogens, both in vitro and in animal models. Here, we demonstrated that Retro-2 and its derivatives, Retro-2.1 and compound 25, blocked infection by Ebola virus and Marburg virus in vitro...
November 21, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29170916/development-of-small-molecule-viral-inhibitors-targeting-various-stages-of-the-life-cycle-of-emerging-and-re-emerging-viruses
#17
REVIEW
Xiaohuan Wang, Peng Zou, Fan Wu, Lu Lu, Shibo Jiang
In recent years, unexpected outbreaks of infectious diseases caused by emerging and re-emerging viruses have become more frequent, which is possibly due to environmental changes. These outbreaks result in the loss of life and economic hardship. Vaccines and therapeutics should be developed for the prevention and treatment of infectious diseases. In this review, we summarize and discuss the latest progress in the development of small-molecule viral inhibitors against highly pathogenic coronaviruses, including severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, Ebola virus, and Zika virus...
November 23, 2017: Frontiers of Medicine
https://www.readbyqxmd.com/read/29163402/pharmacological-induction-of-heme-oxygenase-1-impairs-nuclear-accumulation-of-herpes-simplex-virus-capsids-upon-infection
#18
Francisco J Ibáñez, Mónica A Farías, Angello Retamal-Díaz, Janyra A Espinoza, Alexis M Kalergis, Pablo A González
Heme oxygenase-1 (HO-1) is an inducible enzyme that is expressed in response to physical and chemical stresses, such as ultraviolet radiation, hyperthermia, hypoxia, reactive oxygen species (ROS), as well as cytokines, among others. Its activity can be positively modulated by cobalt protoporphyrin (CoPP) and negatively by tin protoporphirin (SnPP). Once induced, HO-1 degrades iron-containing heme into ferrous iron (Fe(2+)), carbon monoxide (CO) and biliverdin. Importantly, numerous products of HO-1 are cytoprotective with anti-apoptotic, anti-oxidant, anti-inflammatory, and anti-cancer effects...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29161839/the-potential-impact-of-a-prophylactic-vaccine-for-ebola-in-sierra-leone
#19
Erin N Bodine, Connor Cook, Mikayla Shorten
The 2014 outbreak of Ebola virus disease (EVD) in West Africa was multinational and of an unprecedented scale primarily affecting the countries of Guinea, Liberia, and Sierra Leone. One of the qualities that makes EVD of high public concern is its potential for extremely high mortality rates (up to 90%). A prophylactic vaccine for ebolavirus (rVSV-ZEBOV) has been developed, and clinical trials show near-perfect efficacy. We have developed an ordinary differential equations model that simulates an EVD epidemic and takes into account (1) transmission through contact with infectious EVD individuals and deceased EVD bodies, (2) the heterogeneity of the risk of becoming infected with EVD, and (3) the increased survival rate of infected EVD patients due to greater access to trained healthcare providers...
April 1, 2018: Mathematical Biosciences and Engineering: MBE
https://www.readbyqxmd.com/read/29155670/lessons-learned-from-emergency-response-vaccination-efforts-for-cholera-typhoid-yellow-fever-and-ebola
#20
Jenny A Walldorf, Kashmira A Date, Nandini Sreenivasan, Jennifer B Harris, Terri B Hyde
Countries must be prepared to respond to public health threats associated with emergencies, such as natural disasters, sociopolitical conflicts, or uncontrolled disease outbreaks. Rapid vaccination of populations vulnerable to epidemic-prone vaccine-preventable diseases is a major component of emergency response. Emergency vaccination planning presents challenges, including how to predict resource needs, expand vaccine availability during global shortages, and address regulatory barriers to deliver new products...
December 2017: Emerging Infectious Diseases
keyword
keyword
41124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"